Glucotrack has successfully completed its first in-human clinical study for the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein.

Allison Moloney, Community Matron, Torbay and South Devon NHS Foundation Trust. Background of change and intervention As the COVID-19 pandemic escalated, this case study reported that local primary ...

US FDA alerts patients of potential to miss critical safety alerts due to phone settings when using smartphone-compatible diabetes devices: Maryland Friday, February 7, 2025, 09:0 ...

Health-related technologies have evolved significantly in the modern world, offering people innovative tools to manage their ...

This important study shows that the activity of hypothalamic hypocretin/orexin neurons (HONs) correlates with body movement over multiple behaviors. Sophisticated techniques and analyses showcase this ...

Gonzaga University and the UW School of Medicine hosted Irl Hirsch to lecture about the future of glucose monitoring.

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

Managing diabetes is even harder when temperatures and humidity are rising. Find out how extreme heat can negatively affect ...

Researchers have devised a revolutionary, noninvasive method to monitor blood glucose, allowing for accurate measurements of ...

New data reveals 27 Indigenous children in Australia attempted self-harm in prison last financial year, the National ...

Introduction to Digital Health and WellnessThe digital health and wellness industry is experiencing significant growth as healthcare increasingly incorporates technology to improve the quality, ...

RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ: GCTK), a medical technology company, announced the successful completion of its first in human clinical study for a novel continuous glucose monitoring ...